基于GPCR靶点开发新型抗抑郁药的研究进展
本综述聚焦于G蛋白偶联受体(GPCR)如何介导抗抑郁作用,并讨论GPCR调控重性抑郁障碍(MDD)病理生理学的最新见解。文章还探讨了具有配体选择性、表达模式或药理特征优势的新型GPCR靶点的治疗潜力,并强调GPCR药理学与结构研究进展为药物开发提供的新途径。
要点
- 传统抗抑郁药多作用于单胺能转运或降解系统,起效需数周且部分患者抵抗。
- 直接靶向GPCR可能实现更有效和更快的抗抑郁作用。
- 新型GPCR靶点因配体选择性、表达模式或药理特征而具治疗吸引力。
核心结论
- 靶向GPCR可能比传统单胺能系统干预更有效且起效更快地发挥抗抑郁作用。
研究设计与样本
- 本文为综述,未报告系统检索范围或样本量。
主要发现
- 传统抗抑郁药主要干扰单胺能转运或降解系统,起效需数周,且大部分抑郁患者对其抵抗。
- 若干非典型抗抑郁药通过作用于GPCR而非单胺能系统发挥效应。
- 不同GPCR介导抗抑郁作用,并调控重性抑郁障碍的病理生理学。
临床怎么用
- 关注GPCR靶点作为开发更有效、起效更快抗抑郁药的潜在方向。
局限性
- 原文未报告综述的检索范围、纳入标准或证据等级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Traditional antidepressants largely interfere with monoaminergic transport or degradation systems, taking several weeks to have their therapeutic actions. Moreover, a large proportion of depressed patients are resistant to these therapies. Several atypical antidepressants have been developed which interact with G protein coupled receptors (GPCRs) instead, as direct targeting of receptors may achieve more efficacious and faster antidepressant actions. The focus of this review is to provide an update on how distinct GPCRs mediate antidepressant actions and discuss recent insights into how GPCRs regulate the pathophysiology of Major Depressive Disorder (MDD). We also discuss the therapeutic potential of novel GPCR targets, which are appealing due to their ligand selectivity, expression pattern, or pharmacological profiles. Finally, we highlight recent advances in understanding GPCR pharmacology and structure, and how they may provide new avenues for drug development.
引用
- Mantas I, Saarinen M, Xu ZD, et al. Update on GPCR-based targets for the development of novel antidepressants. Mol Psychiatry. 2021. PMID: 33589739. doi:10.1038/s41380-021-01040-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。